Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone33-1-81-69-16-00
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$33.72 million
Profitability
Miscellaneous
Employees131
OptionableOptionable
Cellectis (NASDAQ:CLLS) Frequently Asked Questions
What is Cellectis' stock symbol?
Cellectis trades on the NASDAQ under the ticker symbol "CLLS."
How were Cellectis' earnings last quarter?
Cellectis SA (NASDAQ:CLLS) issued its quarterly earnings results on Tuesday, November, 13th. The biotechnology company reported ($0.54) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.08. The biotechnology company had revenue of $2.19 million for the quarter, compared to analyst estimates of $10 million. Cellectis had a negative return on equity of 21.72% and a negative net margin of 324.07%. View Cellectis' Earnings History.
When is Cellectis' next earnings date?
What price target have analysts set for CLLS?
5 Wall Street analysts have issued twelve-month price objectives for Cellectis' shares. Their forecasts range from $25.00 to $73.00. On average, they expect Cellectis' share price to reach $48.00 in the next twelve months. This suggests a possible upside of 186.7% from the stock's current price. View Analyst Price Targets for Cellectis.
What is the consensus analysts' recommendation for Cellectis?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.
Has Cellectis been receiving favorable news coverage?
News headlines about CLLS stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellectis earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the next several days.
Who are some of Cellectis' key competitors?
Some companies that are related to Cellectis include China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Spark Therapeutics (ONCE), Regenxbio (RGNX), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA) and Sangamo Therapeutics (SGMO).
Who are Cellectis' key executives?
Cellectis' management team includes the folowing people:
- Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
- Dr. David J. D. Sourdive, Co-Founder, Exec. VP of Technical Operations & Director (Age 52)
- Mr. Eric Dutang, Chief Financial Officer (Age 45)
- Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
- Mr. Jean Charles Epinat, Chief Technological Officer
When did Cellectis IPO?
(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.
How do I buy shares of Cellectis?
Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectis' stock price today?
One share of CLLS stock can currently be purchased for approximately $16.74.
How big of a company is Cellectis?
Cellectis has a market capitalization of $697.72 million and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 131 workers across the globe.
What is Cellectis' official website?
How can I contact Cellectis?
Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]
MarketBeat Community Rating for Cellectis (NASDAQ CLLS)
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
